Hims & Hers Health, INC Form 4 insider transactions
NYSE
Form 4: Hims & Hers Health CFO Oluyemi Okupe Executes Stock Option and Sells Shares Under 10b5-1 Plan
Hims & Hers Health CFO Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,345 shares of Class A Common Stock at $14.65 per share under a pre-arranged 10b5-1 trading plan.
NYSE
Hims & Hers Health's Chief Operating Officer, Melissa Baird, executed stock option exercises and sales of Class A Common Stock between September 3rd and September 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on September 3, 2024, according to a Form 4 filing with the SEC.
NYSE
Director Christiane Pendarvis of Hims & Hers Health, Inc. sold 7,000 shares of Class A Common Stock on August 27, 2024, at a price of $15.152 per share.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,334 shares of Class A Common Stock on August 20, 2024, at a price of $16.71 per share.
NYSE
Form 4: Hims & Hers Health PAO Irene Becklund Executes Stock Option and Sells Shares Under 10b5-1 Plan
Irene Becklund, PAO of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock on August 16, 2024, under a pre-arranged 10b5-1 trading plan.
NYSE
Oluyemi Okupe, CFO of Hims & Hers Health, exercised stock options to acquire 6,430 shares of Class A Common Stock at $5.01 per share on August 13, 2024.
NYSE
Director Kare Schultz acquired restricted stock units (RSUs) in Hims & Hers Health, Inc. on August 7, 2024, according to a Form 4 filing.
NYSE
Director David B. Wells reports acquisition of 9,935 Restricted Stock Units (RSUs) in Hims & Hers Health, Inc.
NYSE
Director Anja Manuel reports acquisition of 9,935 Restricted Stock Units (RSUs) convertible to Class A Common Stock of Hims & Hers Health, Inc.
NYSE
Form 4: Hims & Hers Health Director, Andrea Perez Garcia, Reports Acquisition of Restricted Stock Units
Andrea Perez Garcia, a director of Hims & Hers Health, Inc., reported the acquisition of 9,935 Restricted Stock Units (RSUs) on August 7, 2024, convertible to Class A Common Stock.
NYSE
Form 4: Hims & Hers Health Director, Christopher D. Payne, Reports Acquisition of Restricted Stock Units
Christopher D. Payne, a director of Hims & Hers Health, Inc., reported the acquisition of 9,935 Restricted Stock Units (RSUs) on August 7, 2024, convertible to Class A Common Stock.
NYSE
Chief Medical Officer Patrick Harrison Carroll received 9,935 Restricted Stock Units (RSUs) convertible to Class A Common Stock, vesting by June 15, 2025, or the 2025 annual meeting, as per a recent SEC Form 4 filing.
NYSE
Form 4: Hims & Hers Health Director, Delos M. Cosgrove, Reports Acquisition of Restricted Stock Units
Director Delos M. Cosgrove reports acquisition of 9,935 Restricted Stock Units (RSUs) in Hims & Hers Health, Inc.
NYSE
Form 4: Hims & Hers Health Director Christiane Pendarvis Reports Acquisition of Restricted Stock Units
Director Christiane Pendarvis reports acquisition of 9,935 Restricted Stock Units (RSUs) convertible to Class A Common Stock in a recent SEC filing.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,334 shares of Class A Common Stock at a price of $17.3 per share on August 6, 2024.
NYSE
Form 4: Hims & Hers Health CEO Andrew Dudum Executes Stock Option and Sells Shares Under 10b5-1 Plan
CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Melissa Baird, COO of Hims & Hers Health, executed stock option exercises and sales of Class A Common Stock between August 5th and August 7th, 2024, according to a pre-arranged Rule 10b5-1 trading plan.
NYSE
Form 4: Hims & Hers Health Executive Michael Chi Executes Stock Options and Sells Shares Under 10b5-1 Plan
Chief Commercial Officer Michael Chi exercised stock options and sold shares of Hims & Hers Health, Inc. under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,335 shares of Class A Common Stock at a price of $20.29 per share on July 23, 2024, under a pre-arranged 10b5-1 trading plan.
NYSE
Chief Commercial Officer Michael Chi of Hims & Hers Health, Inc. exercised stock options and sold shares of Class A Common Stock on July 23 and 24, 2024, according to a Form 4 filing with the SEC.
NYSE
Chief Commercial Officer Michael Chi of Hims & Hers Health, Inc. executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Irene Becklund, PAO of Hims & Hers Health, executed stock option exercises and sales of Class A Common Stock under a pre-arranged 10b5-1 trading plan.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,335 shares of Class A Common Stock at a price of $20.28 on July 9, 2024, according to a Form 4 filing with the SEC.
NYSE
Melissa Baird, COO of Hims & Hers Health, executed stock option exercises and sales of Class A Common Stock between July 5th and July 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on July 3, 2024, according to a Form 4 filing with the SEC.
NYSE
Chief Commercial Officer Michael Chi exercised stock options and sold shares of Hims & Hers Health, Inc. on June 24, 2024, according to a Form 4 filing with the SEC.
NYSE
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,335 shares of Class A Common Stock at a price of $22.18 per share on June 25, 2024, under a pre-arranged 10b5-1 trading plan.
NYSE
Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 11,546 shares of Class A Common Stock at an average price of $22.2146 on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.